164 related articles for article (PubMed ID: 12501017)
1. The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer.
Prior JO; Barghouth G; Delaloye JF; Leyvraz S; Bischof Delaloye A
Nucl Med Commun; 2003 Jan; 24(1):29-36. PubMed ID: 12501017
[TBL] [Abstract][Full Text] [Related]
2. The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumours: a prospective study.
Haubold-Reuter BG; Duewell S; Schilcher BR; Marincek B; von Schulthess GK
Eur J Nucl Med; 1993 Nov; 20(11):1063-9. PubMed ID: 8287874
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value of whole-body MRI and bone scintigraphy in the detection of osseous metastases in patients with breast cancer--A Prospective Double-Blinded Study at two Hospital Centers].
Ohlmann-Knafo S; Kirschbaum M; Fenzl G; Pickuth D
Rofo; 2009 Mar; 181(3):255-63. PubMed ID: 19229791
[TBL] [Abstract][Full Text] [Related]
4. 111In-pentetreotide versus bone scintigraphy in the detection of bony metastases of neuroblastoma.
Juweid ME; Menda Y; O'Dorisio MS; Bushnell D; Blake M; Madsen M; Johnson J; Graham MM
Nucl Med Commun; 2002 Oct; 23(10):983-9. PubMed ID: 12352597
[TBL] [Abstract][Full Text] [Related]
5. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography.
Schirrmeister H; Guhlmann A; Kotzerke J; Santjohanser C; Kühn T; Kreienberg R; Messer P; Nüssle K; Elsner K; Glatting G; Träger H; Neumaier B; Diederichs C; Reske SN
J Clin Oncol; 1999 Aug; 17(8):2381-9. PubMed ID: 10561300
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
7. How does iliac crest bone marrow biopsy compare with imaging in the detection of bone metastases in small cell lung cancer?
Perrin-Resche I; Bizais Y; Buhe T; Fiche M
Eur J Nucl Med; 1993 May; 20(5):420-5. PubMed ID: 8390936
[TBL] [Abstract][Full Text] [Related]
8. Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience.
Teke F; Teke M; Inal A; Kaplan MA; Kucukoner M; Aksu R; Urakci Z; Tasdemir B; Isikdogan A
Asian Pac J Cancer Prev; 2015; 16(1):387-91. PubMed ID: 25640386
[TBL] [Abstract][Full Text] [Related]
9. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography.
Schirrmeister H; Buck A; Guhlmann A; Reske SN
Thyroid; 2001 Jul; 11(7):677-83. PubMed ID: 11484897
[TBL] [Abstract][Full Text] [Related]
10. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
[TBL] [Abstract][Full Text] [Related]
11. [Combined bone marrow and skeletal scintigraphy in osseous and myelogenous diseases].
Hotze A; Löw A; Mahlstedt J; Wolf F
Rofo; 1984 Jun; 140(6):717-23. PubMed ID: 6234628
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodeoxyglucose-positron emission tomography and bone scintigraphy for detecting bone metastases in patients with malignancies of the upper aerodigestive tract.
Kim MR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Oral Oncol; 2008 Feb; 44(2):148-52. PubMed ID: 17350879
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
14. Technetium-99m-labeled antigranulocyte antibody bone marrow scintigraphy.
Lee KH; Chung JK; Choi CW; Jeong JM; Lee DS; Bang YJ; Lee MC; Kim NK; Koh CS
J Nucl Med; 1995 Oct; 36(10):1800-5. PubMed ID: 7562046
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups.
Koizumi M; Motegi K; Koyama M; Terauchi T; Yuasa T; Yonese J
Ann Nucl Med; 2017 Aug; 31(7):521-528. PubMed ID: 28456877
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow scintigraphy in breast cancer.
Bourgeois P; Gassavelis C; Malarme M; Feremans W; Frühling J
Nucl Med Commun; 1989 Jun; 10(6):389-400. PubMed ID: 2788844
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers.
Withofs N; Grayet B; Tancredi T; Rorive A; Mella C; Giacomelli F; Mievis F; Aerts J; Waltregny D; Jerusalem G; Hustinx R
Nucl Med Commun; 2011 Mar; 32(3):168-76. PubMed ID: 21076343
[TBL] [Abstract][Full Text] [Related]
18. [MR tomography and bone marrow scintigraphy in the screening of skeletal metastases in patients with breast carcinoma].
Layer G; Rieker O; Dörr D; Schnakenberg D; Steudel A; Reiser M
Rofo; 1994 May; 160(5):448-52. PubMed ID: 8173054
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of (18)F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis.
Niikura N; Hashimoto J; Kazama T; Koizumi J; Ogiya R; Terao M; Oshitanai R; Morioka T; Tsuda B; Okamura T; Saito Y; Iwaisako K; Iwamoto T; Hayashi N; Imai Y; Tokuda Y
Breast Cancer; 2016 Jul; 23(4):662-7. PubMed ID: 26037335
[TBL] [Abstract][Full Text] [Related]
20. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.
Nicolini A; Ferrari P; Sagripanti A; Carpi A
Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
